MultiHance® is a paramagnetic
contrast agent for use in diagnostic
magnetic resonance imaging (
MRI) of the
liver and central nervous system. MultiHance® is a small molecular weight
chelate, which tightly binds the Gd atom. The substance is excreted partly by the kidneys, partly by the biliary system, which is especially unique.
MultiHance® is indicated, for the detection of focal
liver lesions in patients with known or suspected primary
liver cancer (e.g. hepatocellular carcinoma) or metastatic disease.
MultiHance® is also indicated in
brain MRI and
spine MRI where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced
MRI.
Gd-BOPTA-enhanced
MRA can provide
superior vascular
signal intensity and
SNR, as compared with
Gd-DTPA, due to its higher
relaxivity, even at lower doses.
1 ml of solution MultiHance® contains: (0.5M)
gadobenate dimeglumine 529 mg = gadobenic acid 334 mg + meglumine 195 mg.
Viscosity at 37°C: 5.3 mPa
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based
contrast agents increase the risk for
nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m
2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative
liver transplantation period.